Synmosa Biopharma Corporation
4114.TWO
Get informed when a big investor buys or sells
+ FollowMarket Cap$0
Close$
Share Statistics
| Market cap | - |
|---|---|
| Enterprise Value | - |
| Dividend Yield | $NaN (NaN%) |
| Earnings per Share | $- |
| Beta | - |
| Outstanding Shares | - |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | - |
| Debt to Equity | - |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
$0.41
Average shareholder expectationRevenue Estimate
$1.68 B
Average shareholder expectationNext Earnings Call
Expected Date
November 18, 2026
EPS Estimate
$0.41
Average shareholder expectationRevenue Estimate
$1.75 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Synmosa Biopharma Corporation
495 employees
CEO: Zhihui Lin Synmosa Biopharma Corporation, established in Taipei, Taiwan, in 1980, operates as a dedicated specialty pharmaceutical enterprise. The company manages the entire lifecycle of pharmaceutical and healthcare products, from research and dev...